Large vessel occlusion stroke due to intracranial atherosclerotic disease: identification, medical and interventional treatment, and outcomes
A De Havenon, OO Zaidat, S Amin-Hanjani… - Stroke, 2023 - Am Heart Assoc
Large vessel occlusion stroke due to underlying intracranial atherosclerotic disease (ICAD-
LVO) is prevalent in 10 to 30% of LVOs depending on patient factors such as vascular risk …
LVO) is prevalent in 10 to 30% of LVOs depending on patient factors such as vascular risk …
[HTML][HTML] The Signaling Pathway of the ADP Receptor P2Y12 in the Immune System: Recent Discoveries and New Challenges
P2Y12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its
well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic …
well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic …
24-Hour carotid stent patency and outcomes after endovascular therapy: a multicenter study
Background: Management of extracranial internal carotid artery steno-occlusive lesion
during endovascular therapy remains debated. Stent occlusion within 24 hours of …
during endovascular therapy remains debated. Stent occlusion within 24 hours of …
Aspirin versus aggressive antiplatelet therapy for acute carotid stenting plus thrombectomy in tandem occlusions: ETIS Registry results
G Marnat, S Finistis, R Moreno, I Sibon… - Journal of …, 2023 - jnis.bmj.com
Background Patients treated with acute carotid stenting (CAS) may have higher odds of a
favorable outcome than those treated without CAS during thrombectomy in tandem …
favorable outcome than those treated without CAS during thrombectomy in tandem …
[HTML][HTML] Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review
Background The optimal antiplatelet therapy regimen for certain neuroendovascular
procedures remains unclear. This study investigates the safety and feasibility of intravenous …
procedures remains unclear. This study investigates the safety and feasibility of intravenous …
Emergent Large Vessel Occlusion due to Intracranial Stenosis: Identification, Management, Challenges, and Future Directions
S Al Kasab, TN Nguyen, CP Derdeyn, S Yaghi… - Stroke, 2024 - Am Heart Assoc
This comprehensive literature review focuses on acute stroke related to intracranial
atherosclerotic stenosis (ICAS), with an emphasis on ICAS-large vessel occlusion. ICAS is …
atherosclerotic stenosis (ICAS), with an emphasis on ICAS-large vessel occlusion. ICAS is …
Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures
F Cagnazzo, RA Radu, I Derraz, PH Lefevre… - Journal of …, 2024 - jnis.bmj.com
Background Cangrelor is an intravenous P2Y12 inhibitor with rapid onset and fast offset of
antiplatelet action. Dose adjusted cangrelor based on platelet function testing is suggested …
antiplatelet action. Dose adjusted cangrelor based on platelet function testing is suggested …
Multicenter comparison of antiplatelet treatment strategies for urgent/emergent neuroendovascular stenting
D Holden, CC May, BT Robbins… - Interventional …, 2023 - journals.sagepub.com
Background Emergent neuroendovascular stenting presents challenges for the utilization of
antiplatelet agents. Methods This was a multicenter, retrospective cohort of patients who …
antiplatelet agents. Methods This was a multicenter, retrospective cohort of patients who …
Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions
Objectives Intravenous (IV) periprocedural antiplatelet therapy (APT) for patients undergoing
acute carotid stenting during mechanical thrombectomy (MT) is not fully investigated. We …
acute carotid stenting during mechanical thrombectomy (MT) is not fully investigated. We …
Genotype-guided dual antiplatelet therapy in cerebrovascular disease: assessing the risk and benefits for ethnic populations
K Qureshi, MU Farooq, PB Gorelick - Expert review of …, 2023 - Taylor & Francis
Introduction Cerebrovascular disease is a leading cause of morbidity and mortality in the
world and antiplatelet therapy is a main pharmacologic means of secondary prevention …
world and antiplatelet therapy is a main pharmacologic means of secondary prevention …